Globus Medical, Inc. GMED reported fourth-quarter 2024 adjusted earnings per share (EPS) of 84 cents, which beat the Zacks ...

Welcome to the Globus Medical's fourth quarter and full year 2024 earnings call. At this time, all lines will be on mute, and ...

Globus Medical (NYSE:GMED) shares dipped today despite fourth-quarter results that came in ahead of the consensus forecast.

Detailed price information for Globus Medical Inc (GMED-N) from The Globe and Mail including charting and trades.

In a report released today, David Turkaly from JMP Securities reiterated a Hold rating on Globus Medical (GMED – Research Report). The ...

Wells Fargo analyst Vik Chopra lowered the firm’s price target on Globus Medical (GMED) to $93 from $95 and keeps an Overweight rating on the ...

Globus Medical started 2025 on a solid note, but a deal for loss-making Nevro creates some discomfort among investors. Read ...

Globus Medical expects full-year earnings in the range of $3.40 to $3.50 per share, with revenue in the range of $2.66 billion to $2.69 billion. This story was generated by Automated Insights ( http:/ ...

Detailed price information for Globus Medical Inc (GMED-N) from The Globe and Mail including charting and trades.

Globus Medical saw a strong 2024 with multiple new product launches and more innovation is on the way, President and CEO Dan Scavilla said in a Feb. 20 earnings ...

Globus Medical Inc. (NYSE:GMED), a leading medical device company specializing in musculoskeletal disorders, has been making waves in the healthcare sector with its recent acquisition of Nevro Corp ...